ArticleJCO clinical cancer informatics2025
Evaluating Dimensionality Reduction for Patient-Reported Outcome-Based Survival Modeling in Patients With Head and Neck Cancer.
Article in JCO clinical cancer informatics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Improving Survival Prediction of Head and Neck Cancer Patients by Modeling Long-term Symptom Burden.Proceedings. IEEE International Conference on Healthcare Informatics · 2026Article
- Advancing Normal Tissue Complication Probability Modeling with Supervised Contrastive Learning for Predicting Osteoradionecrosis.Proceedings of the ... Symposium on Applied Computing. Symposium on Applied Computing · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
purposeThis study aims to improve survival modeling in head and neck cancer (HNC) by integrating patient-reported outcomes (PROs) using dimensionality reduction techniques. PROs capture symptom severity across the treatment timeline and offer key insights for personalized care. However, their high dimensionality poses challenges such as overfitting and computational complexity. This work focuses on transforming and incorporating PRO data to enhance model performance in HNC. MATERIALS AND
methodsWe analyzed retrospective data of 923 patients with HNC treated at the University of Texas MD Anderson Cancer Center between 2010 and 2021. Baseline clinical data including demographic, treatment, and disease characteristics were used to build a reference survival model. PRO data, capturing symptom ratings, were integrated using dimensionality reduction techniques: principal component analysis (PCA), autoencoders (AEs), and patient clustering. These reduced representations, combined with clinical data, were input into Cox proportional hazards models to predict overall survival (OS) and progression-free survival (PFS). Model performance was assessed using the concordance index, time-dependent AUC, Brier score for calibration, and hazard ratios for predictor significance.
resultsCox models incorporating PCA and AE outperformed the clinical-only reference model for both OS and PFS. The PCA-based model achieved the highest C-indices (0.74 for OS and 0.64 for PFS), followed by the AE model (0.73 and 0.63) and the clustering model (0.72 and 0.62). Time-dependent AUCs reinforced these results, with PCA showing the highest average AUC over 36 months. All models were well-calibrated, with low Brier scores. Key predictors included age, disease stage, and tumor subsite.
conclusionDimensionality reduction techniques improve survival prediction in patients with HNC by effectively incorporating PRO data, potentially providing greater insights into more personalized treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.